BioCurity Pharmaceuticals Inc. (“BioCurity”), is a clinical-stage biopharmaceutical company with a mission to positively transform radiation therapy for cancer patients, by addressing the global unmet need for an effective treatment to prevent toxicity from radiation therapy (radiation dermatitis). Approximately 6 million of the 18 million people who will be diagnosed with cancer every year, will receive radiation treatment. The lack of an effective treatment for the adverse side effects associated with radiation therapy represents a substantial market opportunity, but most importantly, a chance to help better the quality of life for cancer survivors around the world. BioCurity’s patented technologies and drugs in their pipeline have the potential to significantly reduce radiation toxicity for newly diagnosed patients as well as the millions of cancer patients who continue to receive radiation as a part of their ongoing treatment for cancer.